On the Battlefront
Around 40.000 people are diagnosed with cancer each day worldwide. That adds up to more than 14 million people every year.
In the field of Oncology, we hear about new risk factors, mutations and pathologic mechanisms every day. Novel approaches and therapeutics are being tested daily and changing the paradigm of this disease.
In 8th AIMS Meeting, you will have the chance to learn about the newest and most exciting discoveries in this field and have the opportunity to meet the scientists and doctors that are making a change!
Come join us in this battlefront!
Principal Investigator, Head of Systems Oncology Group – Champalimaud Centre for the Unknown
Professor Bruno Costa-Silva concluded his baccalaureate in Pharmacy and Biochemistry in 2005, at the Federal University of Santa Catarina, Brazil. Also there, he completed his MSc degree in Cellular and Molecular Neurosciences, in 2007. During his Ph.D. studies in Oncology, at the AC Camargo Hospital, he worked with Dr. Vilma Regina Martins at the Ludwig Institute for Cancer Research (Brazil) and Dr. David Lyden at Weill Cornell Medical College (USA). From 2013 to 2015, as a visiting scientist at Memorial Sloan Kettering Cancer Center, collaborated with Dr. Richard Kolesnick. In 2016 Professor Costa-Silva moved to the Champalimaud Centre for the Unknown in Lisbon, as Head of Systems Oncology Group.
Currently his main work is centered in the non-tumor cells and the way they affect tumors and their prognostic. This communication can be mediated via extracellular vesicles, which can be detected in the circulation through “liquid biopsies”.
As something to achieve in the future, in his own words, “we may learn how to turn a tumor into a chronic disease”, cementing the idea of a translational investigation being pursuit.
Senior Investigator, Molecular Oncology Lab – Candiolo Cancer Institute – IRCCS; President of the Italian National Association of Biotechnology
Professor Sabrina Arena graduated in Medical Biotechnology in 2002, from the Faculty of Medicine in the University of Turin. The following four years, she spent exchanging between both the Institute for Cancer research and Treatment at the University of Turin and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, as a PhD student. In the 2010-15 period professor Sabrina Arena went through Medical Residency in Clinical Pathology.
On the present day, Professor Arena is the president of the Italian National AssociationofBiotechnology (AssociazioneNazionaleBiotecnologiItaliani-ANBI)andisa senior researcher at Alberto Bardelli’s Lab in the University of Torino & Candiolo Cancer Institute, studying clonal evolution and drug resistance in cancer.
Coordinator of the Investigation Centre of Brain Tumors (Centro de Investigação de Tumores Cerebrais); Neurosurgery Department HSM; Senior Investigator IMM
Professor Cláudia Faria, neurosurgeon at Santa Maria Hospital, has been working for several years in the field of pediatric neuro oncology. Having concluded her residency in neurosurgery at Hospital de Santa Maria in 2010, in the same year she started her PhD studies at Labatt Brain Tumour Research Centre Hospital for Sick Children, in Toronto (Canada). During the following three years, Professor Cláudia Faria studied the most agressive pediatric brain tumor – medulloblastoma – identifying new therapeutic molecular targets.
Currently in Lisbon, she has been working as a neurosurgeon in Santa Maria Hospital and investigator at Instituto de Medicina Molecular, dedicating her career to the study of pediatric brain tumors. Professor Cláudia Faria is the coordinator of the Investigation Centre of Brain Tumors (Centro de Investigação de Tumores Cerebrais), ennabling the creation of a Brain Tumor Bank included in Biobanco-IMM, and investigating the brain tumor’s molecular biology which allowed to identify new ways to approach the disease.